Gene · 4507
Papers2,281
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,281
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models. | Clin Cancer Res | 2025 | 40553452 | PubTator, text mining | PubMed |
| Extragonadal Urinary Tract Neoplasms With Yolk Sac Differentiation: Clinical, Histologic, and Molecular Evidence of Derivation From Underlying Urothelial Carcinoma. | Mod Pathol | 2025 | 40550467 | PubTator, text mining | PubMed |
| Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities. | Diagnostics (Basel) | 2025 | 40506895 | PubTator, text mining | PubMed |
| Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study. | ESMO Open | 2025 | 40499462 | PubTator, text mining | PubMed |
| Assessment of CDKN2A homozygous and heterozygous deletions in gliomas across multiple detection platforms. | BMC Cancer | 2025 | 40474207 | PubTator, text mining | PubMed |
| Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models. | Cell Death Discov | 2025 | 40450009 | PubTator, text mining | PubMed |
| A comparison of CDKN2A status in gliomas using different techniques: The loss of p16 as a surrogate marker. | J Neuropathol Exp Neurol | 2025 | 40445894 | PubTator, text mining | PubMed |
| Discovery and Mechanism of 16-19F, a Novel Synthetic Lethal Inhibitor of the PRMT5•MTA Complex in MTAP-Deleted Cancer Cells. | ACS Chem Biol | 2025 | 40440106 | PubTator, text mining | PubMed |
| Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss-No Target Is Out of the Realm of Possibility. | Am Soc Clin Oncol Educ Book | 2025 | 40435431 | PubTator, text mining | PubMed |
| Discovery of Potential Scaffolds for Methionine Adenosyltransferase 2A (MAT2A) Inhibitors: Virtual Screening, Synthesis, and Biological Evaluation. | Molecules | 2025 | 40430308 | PubTator, text mining | PubMed |
| MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screens. | Proc Natl Acad Sci U S A | 2025 | 40377999 | PubTator, text mining | PubMed |
| Genomic profiling and pathological assessment of malignant peripheral nerve sheath tumors. | J Cancer Res Clin Oncol | 2025 | 40369172 | PubTator, text mining | PubMed |
| Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma. | Int J Mol Sci | 2025 | 40362535 | PubTator, text mining | PubMed |
| Genetic re-classification of combined hepatocellular-cholangiocarcinoma and small duct type intrahepatic cholangiocarcinoma. | Pathol Res Pract | 2025 | 40349569 | PubTator, text mining | PubMed |
| ERS Congress 2024: highlights from the Thoracic Oncology Assembly. | ERJ Open Res | 2025 | 40264456 | PubTator, text mining | PubMed |
| MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review. | J Neuropathol Exp Neurol | 2025 | 40249413 | PubTator, text mining | PubMed |
| CD5 Immunoreactivity Is Associated With Longer Overall Survival in Thymic Carcinoma: A Brief Report. | JTO Clin Res Rep | 2025 | 40242668 | PubTator, text mining | PubMed |
| Structure-Based Discovery of a Series of Novel MAT2a Inhibitors. | ACS Med Chem Lett | 2025 | 40236535 | PubTator, text mining | PubMed |
| Deficiency of MTAP Is Frequent and Mostly Homogeneous in Pancreatic Ductal Adenocarcinomas. | Cancers (Basel) | 2025 | 40227771 | PubTator, text mining | PubMed |
| Pitfalls in the evaluation of CDKN2A copy number status in meningioma. | J Neurooncol | 2025 | 40227557 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4507/papers?page=13